Ann: Beam Receives Follow Up US$3M Order, page-14

Ambitous' comments are pretty much reflected in the Q1 commentary - still not acheiving the necesary top line growth.

Also of concern is the seemingly never-ending R&D investment ahead of sales, given the rather short product shelf life.

Still very cheap, but I don't like the lack of earnings visibility (and the high dependence on one-off contracts).

However, it is a far improved investment proposition (given its debt free balance sheet, and succesful commercialisation of GO) than 6 months ago.